secwatch.observer — SEC 8-K summary
======================================

Issuer:     Instil Bio, Inc. (TIL)
CIK:        0001789769
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001789769-25-000074
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

ImmuneOnco reports 62% partial response rate in Phase 2 NSCLC trial of IMM2510 + chemo
--------------------------------------------------------------------------------

- As of July 1, 2025, 33 patients dosed at 10 mg/kg; 21 efficacy-evaluable patients.
- Partial responses in 62% of evaluable: 80% (8/10) squamous NSCLC, 46% (5/11) non-squamous.
- No dose-limiting toxicities; only one TRAE leading to drug discontinuation; low-grade irAEs.
- ImmuneOnco expects to present full data at a future medical conference.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000074/0001789769-25-000074-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789769/000178976925000074/til-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001789769-25-000074

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer